Bioprocess validation techniques help ensure that the manufacturing process is capable of consistently delivering quality products that meet pre-determined specifications and quality standards. Bioprocess validation techniques involve qualitative and quantitative approaches to collect and analyze data regarding the facility, utilities, equipment, materials, components, drug product attributes, manufacturing processes, cleaning procedures, and computerized systems.
The global Bioprocess Validation Market is estimated to be valued at US$ 411.04 Mn in 2023 and is expected to exhibit a CAGR of 5.6% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Technological advancements in bioprocess validation is one of the major trends driving growth of the bioprocess validation market. Key players are focusing on developing innovative techniques and tools to streamline validation processes and technologies for continuous bioprocessing. For instance, in 2021, 3DBiomatrix introduced a range of bioreactor technology including single-use bioreactors to facilitate continuous and automated validation of biomanufacturing processes. The company’s novel bioreactor technology helps accelerate product development cycles and reduce validation timelines through continuous process monitoring and control. Such developments are expected to positively impact the adoption of bioprocess validation techniques over the forecast period.
Segment Analysis
The global bioprocess validation market is dominated by the upfront segment. This is because upfront validation is required to be performed before the production of biotherapeutics to ensure product quality and purity. It accounts for over 60% of the market share as comprehensive testing and documentation is required as per regulatory guidelines prior to the commercial production of biologic drugs and therapies.
Key Takeaways
The global Bioprocess Validation Market Demand is expected to witness high growth over the forecast period of 2024 to 2031 supported by increasing demand for biologics and stringent regulatory norms governing their production. The global Bioprocess Validation Market is estimated to be valued at US$ 411.04 Mn in 2023 and is expected to exhibit a CAGR of 5.6% over the forecast period 2024 to 2031.
Regional analysis: North America currently dominates the global market and is expected to maintain its leading position throughout the forecast period. High biopharmaceutical research activities in the US and rising production of advanced biologics drive the North American market. The Asia Pacific region is projected to be the fastest growing market attributed to increasing investments by major players, rising contract research and manufacturing activities in countries like China and India.
Key players: Key players operating in the bioprocess validation market are GSK Plc (U.K.), TheraVida (U.S.), Revance (U.S.)., NovaMedica. (Russia), Ulthera, Inc. (U.S.), DEMIRA e.V (Germany), Abbvie, Inc (U.S.), Fresh Tracks Therapeutics, Inc. (U.S.), Dr. August Wolff GmbH (Germany), Dermavant Sciences, Inc. (U.S.), Eirion Therapeutics, Inc (U.K.). These players are focusing on new product launches, facility expansions and acquisitions to strengthen their market position.
Explore more related article on this topic: https://www.ukwebwire.com/biopharmaceutical-industry-is-driving-the-bioprocess-validation-market/
https://techaxen.com/game-engines-powering-the-future-of-gaming/
Comments
0 comment